Changes in Soluble CEA and TIMP-1 Levels during Adjuvant Chemotherapy for Stage III Colon Cancer
|
|
- Stephen Russell
- 5 years ago
- Views:
Transcription
1 Changes in Soluble CEA and TIMP-1 Levels during Adjuvant Chemotherapy for Stage III Colon Cancer BAHIR ALDULAYMI 1, IB J. CHRISTENSEN 2, GYÖRGY SÖLÉTORMOS 3, PER JESS 1, SVEND ERIK NIELSEN 4, NILS BRÜNNER 5 and HANS J. NIELSEN 6 Departments of 1 Surgery, 3 Clinical Biochemistry, and 4 Oncology, Hillerød Hospital, Hillerød, Denmark; 2 Finsen Laboratory, Copenhagen Biocenter, Copenhagen, Denmark; 5 Department of Veterinary Disease Biology, Faculty of Life Science, University of Copenhagen, Frederiksberg, Denmark; 6 Department of Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark Abstract. Background: Tissue inhibitor of metalloproteinases- 1 (TIMP-1) has been suggested to be a valuable marker in colorectal cancer (CRC), but the effects of chemotherapy on TIMP-1 levels are unknown. The present study evaluated the effect of chemotherapy on TIMP-1 levels in comparison with carcinoembryonic antigen (CEA) levels in patients with stage III colon cancer. Patients and Methods: Thirty patients who had been curatively resected for stage III colon cancer were included. The patients received cycles of modified FOLFOX6 regimen. Blood samples were collected before and after the first and the second cycle and three months later. Results: No significant change could be detected in CEA levels while TIMP-1 raised significantly after the second cycle but returned to normal 3 months later. Conclusion: Plasma CEA levels are stable during adjuvant chemotherapy while the plasma level of TIMP-1 might be directly affected by chemotherapy represented by a transient rise about 2 weeks following the initiation of treatment. Colorectal cancer (CRC) is one of the most common malignancies of the aging population and the third leading cause of cancer-related death in the industrialized part of the world (1). Approximately 80% of the patients diagnosed with primary CRC undergo intended curative resection, while 20% may be offered only palliative treatment. Despite curative surgery patients still have a significant and stage dependent risk of developing recurrent disease within the next 5 years. Towards improving that, much interest has been focused on enhancing the effect of adjuvant treatment modalities to eliminate microscopic disease and thus reduce Correspondence to: Bahir Aldulaymi, MD, Department of Surgery, Hillerød Hospital, DK-3400 Hilleroed, Denmark. Tel: , bal@noh.regionh.dk Key Words: Colon cancer, chemotherapy, CEA, TIMP-1. the risk of recurrence. 5-Fluorouracil (5-FU) has been the main chemotherapeutic agent for decades. The introduction of oxaliplatin has further increased the efficacy of adjuvant treatment (2-4). However, the majority of the patients receiving adjuvant chemotherapy have no benefit from the treatment, either because they do not have residual disease or because the residual tumor cells are resistant to the administered drugs. The prediction of response has therefore been the main concern for oncologists and gastroenterologists. Potentially, predictive biomarkers might be useful for identifying patients, who would benefit from a certain treatment modality and in addition protect those patients, who would not benefit, from ineffective treatment and thereby from the adverse effects induced by chemotherapy. Such patients might benefit from other treatment modalities. Carcinoembryonic antigen (CEA) is still the only recommended biological marker in CRC. It is recommended for monitoring purposes during and after systemic therapy, as persistently raised values above baseline might suggest recurrent or progressive disease (5, 6). However the interpretation of CEA measurements into clinical decisionmaking has its limitations. CEA levels may rise in patients without recurrence, and may even be below the cut-off point of 5 μg/l in patients with disseminated disease. Therefore, additional biological markers are needed to improve the identification of patients at risk of recurrent disease after intended curative resection and to monitor such patients during and after adjuvant therapy. One of the new biological markers that may be of value either as a single marker or in combination with CEA is soluble tissue inhibitor of metalloproteinases-1 (TIMP-1). TIMP-1 is a member of the natural matrix metalloproteinase (MMPs) inhibitor family. MMPs are zinc-dependent enzymes that collectively may degrade all components of the extracellular matrix (7). Presently, four members of the TIMP family have been identified (TIMP-1-4). The balance /2010 $
2 Table I. Modified FOLFOX6 regimen. 5-FU* 400 mg/m 2 bolus on day mg/m 2 IVCI** over 46 hours on days 1 and 2 LV*** 400 mg/m 2 over 2 hours on day 1 Oxaliplatin 85 mg/m 2 on day 1 *5-Fluorouracil; **intravenous continuous infusion; ***leucovorin. between MMPs and TIMPs regulates the extracellular matrix (ECM) turnover and remodeling during normal development and disease. In addition to its inhibitory role TIMP-1 also possesses specific effects as TIMP-1 may stimulate cell growth, participate in angiogenesis regulation and inhibit apoptosis (7). Thereby, TIMP-1 may have dual roles as a protective against tumor dissemination and as a promoter of tumor growth (8). Previous studies have shown that patients with CRC have significantly increased plasma TIMP-1 levels compared to healthy individuals (9, 10). More importantly, TIMP-1 has been shown to detect early-stage colon cancer with sensitivity and specificity comparable to those of late stages (9). It has recently been shown that plasma TIMP-1 levels are significantly and independently associated with objective response, time to progression, and overall survival in patients with metastatic CRC receiving combination chemotherapy (11). In addition, it has been shown that plasma TIMP-1 levels predicted the prognosis of CRC patients independent of clinical parameters including Dukes stage (9, 12). On this basis, plasma TIMP-1 has been suggested as a biomarker to be used for monitoring CRC patients, both as a single entity and in combination with CEA (10). While it is well established that CEA levels may change in individual patients during chemotherapy, this phenomenon has not been investiagted for TIMP-1. Therefore, the aim of the present study was to evaluate the effect of adjuvant chemotherapy on TIMP-1 levels in comparison with CEA levels in stage III colon cancer patients. Patients and Methods Thirty patients (14 males and 16 females, median age 63) with primary colon cancer, who had been intended curatively resected for stage III disease (TNM stage: T 1-4, N 1-3, M 0 ) and scheduled for adjuvant chemotherapy, were prospectively and consecutively included at the time of outpatient visit before the initiation of chemotherapy. Exclusion criteria were current infection, previous chemotherapy, severe uncontrolled diabetes or any other serious medical conditions that hindered treatment with chemotherapy. The study was performed according to the Helsinki II declaration and was approved by The National Ethics Committee (KF /03) and The Danish Data Protection Agency ( ). Written informed consent was obtained from all the included patients. The patients received cycles of chemotherapy of a modified FOLFOX 6 regimen (Table I). Blood samples were collected from an antecubital vein using a light tourniquet just before and just after the first cycle (day 0 and day 2, respectively), just before and just after the second cycle (day 16 and day 18, respectively) and three months later, just before the seventh cycle (day 110). The samples were collected at room temperature using endotoxin-free tubes (Becton-Dickinson, Mountain View, CA, USA). No additives were included in the tubes for serum, while EDTA was used as anticoagulation agent in the tubes for plasma. The plasma samples were inverted at least five times, and all the collected samples were stored at room temperature for a maximum of two hours. Subsequent centrifugation was performed at 3000xg for 10 min at 21 C. The serum and plasma supernatants were transferred to 2 ml cryo-tubes (TechNunc; Roskilde, Denmark) without disturbing the cell pellet, by leaving 5 mm plasma over the buffy-coat. All the blood aliquots were stored at 80 C until analyses. CEA analysis. The serum CEA concentration in each sample was determined by a single measurement using an automated ADVIA Centaur analyzer (Siemens Healthcare Diagnostics Inc, Deerfield, USA). The CEA assay is a two-sited sandwich immunoassay using direct chemiluminometric technology. The first antibody, in the Lite reagent, is a purified polyclonal rabbit anti-cea antibody labeled with acridinium ester. The second antibody, in the solid phase, is a monoclonal mouse anti-cea antibody covalently coupled to paramagnetic particles. The measuring range of the assay system was 0.5 μg/l to 150 μg/l; samples with concentrations below 0.5 μg/l were considered 0 μg/l, while samples with concentrations above the measuring range were diluted and reanalyzed. To ensure a stable analytical quality over time, two control samples having different concentrations of CEA were included in each assay run. The Westgard rule (1-2SD) was used to accept or reject runs. The assay variability was <7%. TIMP-1 analysis. Soluble TIMP-1 levels were determined in EDTA plasma by use of an in-house TIMP-1 ELISA, which previously has been rigorously validated and demonstrates low intra- and interassay coefficients of variation (CV) (7). In brief, for measurements of TIMP-1 protein levels, microtiter plates were coated with a sheep polyclonal antibody and detection of bound TIMP-1 (free and complex-bound forms) was carried out by the use of a monoclonal antibody (MAC 15) and a secondary alkaline phosphatase coupled anti-mouse antibody (DAKO). Readings of color development were taken every 10 min for 1 h and the calculations of concentrations were based on included recombinant TIMP-1 protein standards. The TIMP-1 cut-off level was μg/l (13). Intra- and inter assay variations were below 10%. Statistics. A general linear model with repeated measurements was used to analyze the TIMP-1 and CEA levels at day 0, 2, 16, 18 and 110. TIMP-1 and CEA values were log transformed and estimates were obtained using generalized estimating equations with patient as the clustering variable. 234
3 Aldulaymi et al: CEA and TIMP-1 during Adjuvant Chemotherapy for Stage III Color Cancer Figure 1. Changes in plasma CEA during the first and second cycle of chemotherapy and three months later. CEA is relatively stable during chemotherapy. Figure 2. Changes in plasma TIMP-1 concentration during the first and second cycles of chemotherapy and three months later. There is a transit raise around day 18. The variables were summarized by mean and confidence intervals (CI). P-values lower than 0.05 were considered significant. All the calculations were performed using the statistical software SPSS (SPSS Inc. Chicago, USA) version or SAS (SAS Institute Inc., NC, USA) version 9.1. Results CEA. Three patients had elevated CEA levels of more than 5 μg/l before the initiation of treatment. Three patients on day 2, 3 patients on day 16, 1 patient on day 18 and 2 patients on day 110 had elevated CEA levels above the cut-off point. The CEA level was relatively stable during the study and none of the patients had sustained CEA elevation throughout the study. The mean CEA level before (day 0) and after the first cycle of treatment (day 2) was 1.66 μg/l and 1.16 μg/l respectively, (p=0.06). At the second cycle (day 16 and 18) the mean level was 1.71 μg/ll and 1.69 μg/l respectively, (p=0.94). At the three month visit (day 110) the mean CEA level was 1.61 μg/l before the infusion of chemotherapy, Figure 1. TIMP-1. Twenty-five patients had an elevated TIMP-1 level above the cut-off value ( μg/l) at day 0 (before the initiation of chemotherapy) In addition, 26 patients at day 2, 25 patients at day 16, 24 patients at day 18, and 17 patients at day 110 had elevated levels above the cut-off value. Ten patients had sustained elevation of TIMP-1 levels throughout the study. The mean plasma TIMP-1 level before (day 0) and after the first treatment cycle (day 2) was μg/l and μg/l respectively, (p=0.74). Before and after the second cycle (day 16 and 18) TIMP- 1 mean level was μg/l and μg/l respectively. The level at day 18 was 15% higher than at day 16 (p=0.34) and was also significantly (26%) higher than pretreatment level, (p=0.038). At the third month before the seventh cycle (day 110) the mean level of plasma TIMP-1 was μg/l, 31% lower than the level at day 18, (p=0.013), Figure 2. Clinical evaluation. Clinical evaluation, endoscopy and thoraco-abdominal computer tomography examination 6 months following surgery revealed no signs of recurrence in any of the patients. Discussion There were two major findings of the present study. Firstly, the serum CEA levels were relatively stable during chemotherapy treatment. Secondly, the plasma TIMP-1 levels appeared to be influenced by the chemotherapy, observed as a significant, but transient increase in mean plasma TIMP-1 level at day 18, just after chemotherapy. The mean level of the plasma TIMP-1 decreased significantly from day 18 and returned to baseline levels at day 110 just before the seventh cycle of chemotherapy. It was previously shown that elevated CEA levels above 5 μg/l in patients who subsequently underwent intended curative resection for primary CRC (n=181) returned to normal (below 5 μg/l ) in 73% (n=133) of the cases, while sustained elevation was observed in 27% (n= 48) of the patients four weeks following surgery (14). Patients with sustained high postoperative CEA levels had a worse prognosis compared to the patients, in whom postoperative CEA levels returned to normal (14). Based on the current literature demonstrting a CEA surge induced by chemotherapy in patients with 235
4 metastatic CRC (15, 16), it was presumed that the adjuvant therapy given in the present study would also induce transient increase in CEA levels. However, a slight decrease in serum CEA was observed after the first cycle of chemotherapy, but the decrease was clinically irrelevant as the mean levels were far below the standard cut-off point of 5 μg/l. The differences in CEA reaction to chemotherapy in stage III and stage IV patients are poorly understood. It is plausible that some chemotherapeutic agents might enhance CEA-mRNA expression in tumor cells resulting in a transient rise in CEA followed by subsequent decline due to enhanced apoptosis. This is supported by a previous study showing that treatment of the human colon cancer cell line COLC201 with 5-FU increased the expression of CEA- mrna and the addition of a platinum to 5-FU enhanced this expression (17). The lack of an overt tumor burden in stage III compared to stage IV patients might also explain why such changes could not be reproduced in the current study. The TIMP-1 protein is stored in granules in platelets and leukocytes and is released upon activation or due to disintegration of the cellular elements (18). It is also expressed by myofibroblasts in association with invading colon cancer cells (19). Previous studies showed that high preoperative plasma TIMP-1 levels could be maintained up to 3 months following curative resection for primary disease (13, 20). Therefore, stage III patients receiving chemotherapy, which is initiated approximately four weeks after intended curative resection, may still have plasma TIMP-1 levels in the range of preoperative levels. As shown in the present study, the mean plasma TIMP-1 levels increased significantly during chemotherapy. No clear correlation between this increase in TIMP-1 and patient outcome was found during short-term follow up, as radiological, endoscopic and clinical evaluations revealed no signs of recurrence six month after the operation in any of the patients. The mechanism behind the observed increase in plasma TIMP-1 is still unclear, but may be related to cellular disintegration (tumour cells and/or blood cells) with subsequent release of soluble TIMP-1. The disintegration of platelets induced by chemotherapy (21, 22) and in particular to oxaliplatin is well-described (23-25) and might contribute to raising the TIMP-1 level. Whether leucocytes were disintegrated as well is unknown, but potential disintegration of neutrophils would also add to TIMP-1 levels. Another plausible explanation could be the up-regulation of TIMP-1 synthesis and release as a reaction to apoptosis induced by the chemotherapy. In support of this hypothesis, it has been shown previously that TIMP-1 possesses anti-apoptotic effects (26-28), which might be enhanced by administer chemotherapy. Whether this transient increase in TIMP-1 predicts favourable prognosis reflecting more effective cell killing or predicts a poor outcome reflecting enhanced TIMP-1 mediated resistance to apoptosis is still unclear. It is concluded that chemotherapy (FOLFOX6 regimen) results in increasing mean plasma TIMP-1 levels. Whether CEA and TIMP-1 could be used to detect recurrence or metastases during chemotherapy could not be shown in the present limited study, which only evaluated the direct effect of chemotherapy on the kinetics of these two biomarkers. However, that question may be answered in subsequent wellpowered prospective studies. Acknowledgements The authors thank Ms. Margit Rytkoenen, Ms. Birgitte Sander Nielsen and Ms. Merete Frejstrup Pedersen for their skilful assistance in this study. The study received financial support from: Region-3 Fund, The Research pool 2006, The Tvergaard Fund, The Olga Bryde Nielsen Fund, The Helen Rude Fund, The Inger and Håkon Fabricius Fund, Scientific Research Forum of East Denmark, The Dagny and Andreas Johansen Fund, (Lægernes Forsikringsforening af 1891), The Kornerup Fund, The Aase and Ejnar Danielsen Fund, The Aage and Johanne Louis-Hansen Fund, The Walter and O. Kristiane Christensen Fund, The Danish Cancer Society (HJN is Danish Cancer Society Professor of Surgical Oncology) and the Danish Strategic Research Foundation (FØSU). References 1 O Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96(19): , Eggington S et al: Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 95(9): , Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 134(5): , Andre T et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23): , Locker GY et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33): , Duffy MJ et al: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43(9): , Moller Sorensen N et al: Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 43(7): , Chirco R et al: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25(1): , Holten-Andersen MN et al: Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8(1): , Waas ET et al: Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48(4): ,
5 Aldulaymi et al: CEA and TIMP-1 during Adjuvant Chemotherapy for Stage III Color Cancer 11 Sorensen NM et al: TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13(14): , Holten-Andersen MN et al: Tissue inhibitor of metalloproteinases- 1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 42(12): , Frederiksen CB, Lomholt AF, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brünner N and Nielsen HJ: Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 29: 75-82, Wang JY et al: Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 39(4): , Sorbye H and Dahl O: Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol 21(23): , Ailawadhi S et al: Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 70(1): 49-53, Ohtsukasa S et al: Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol 129(12): , Holten-Andersen MN et al: Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. Scand J Clin Lab Invest 62(3): , Holten-Andersen MN et al: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer 113(2): , Hammer JH et al: Impact of elective resection on plasma TIMP- 1 levels in patients with colon cancer. Colorectal Dis 8(3): , Bozec L et al: Irinotecan-induced immune thrombocytopenia. Ann Oncol 9(4): , Stokes Z et al: Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer. Gynecol Oncol 97(3): , Sorbye H, Bruserud Y and Dahl O: Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 40(7): , Koutras AK et al: Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 67(2): , Curtis BR et al: Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81(3): , Guedez L et al: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102(11): , Li G, Fridman R and Kim HR: Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59(24): , Murphy FR et al: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277(13): , Received April 19, 2009 Revised December 1, 2009 Accepted December 2,
Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationRESEARCH COMMUNICATION
Preoperative Serum CEA, CA19-9 and CA 125 as Prognostic Factors for Colorectal Cancer RESEARCH COMMUNICATION Preoperative Serum Carcinoembryonic Antigen, Carbohydrate Antigen19-9 and Carbohydrate Antigen
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationKaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi
Case Reports in Surgery Volume 2016, Article ID 4548798, 5 pages http://dx.doi.org/10.1155/2016/4548798 Case Report Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationPharmacy Management Drug Policy
11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor
More informationPreoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer
university of copenhagen Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer Birgisson, Helgi ; Nielsen, Hans J.; Christensen, Ib Jarle; Glimelius,
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationDr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland
Draft Laboratory Testing for Tumour Markers V1.0 Authors Dr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland Dr. Gerard Boran, Consultant Chemical Pathologist,
More informationChanges in Plasma TIMP-1 Levels after Resection for Primary Colorectal Cancer
Changes in Plasma TIMP-1 Levels after Resection for Primary Colorectal Cancer C. FREDERIKSEN 1, A.F. LOMHOLT 1, G.J. DAVIS 2, B.L. DOWELL 2, M.A. BLANKENSTEIN 3, I.J. CHRISTENSEN 4, N. BRÜNNER 5 and H.J.
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationFIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/ WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: ONE CENTER EXPERIENCE RESULTS
PROCEEDINGS FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/ WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: ONE CENTER EXPERIENCE RESULTS Assia Konsoulova, Ivan Donev, Nikolay Conev, Sonya Draganova, Trifon
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationLow-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
Med Oncol (2014) 31:870 DOI 10.1007/s12032-014-0870-2 ORIGINAL PAPER Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer Jasmine Miger Annika Holmqvist Xiao-Feng Sun Maria Albertsson
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationName of Policy: Serum Tumor Markers for Breast and Gastrointestinal Malignancies
Name of Policy: Serum Tumor Markers for Breast and Gastrointestinal Malignancies Policy #: 195 Latest Review Date: October 2013 Category: Medical Policy Grade: A Background/Definitions: As a general rule,
More informationRectal Cancer. GI Practice Guideline
Rectal Cancer GI Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Dr. Francisco Perera MD, FRCPC (Radiation Oncologist) Dr. Jay Engel MD, FRCPC (Surgical Oncologist) Approval Date: 2006 This guideline
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationComparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationCASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION
CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION PROVIDED AS AN EDUCATIONAL SERVICE BY THE INSTITUTE FOR CONTINUING HEALTHCARE EDUCATION SUPPORTED BY AN EDUCATIONAL GRANT FROM GENENTECH LEARNING
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationType Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily
Colorectal - Adjuvant Standard adjuvant therapy for Duke's C Day(s) Drug Dose Route Comments and high risk Duke's B Colorectal cancer 5-FU/FA Weekly 1 Folinic acid 50mg IV IV Bolus injection via fast running
More informationCOLORECTAL CANCER 44
COLORECTAL CANCER 44 Colorectal Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Stuart M. Lichtman, MD Memorial Sloan-Kettering Cancer Center Commack,
More informationRESEARCH ARTICLE. Bo He 1, Hui-Qing Zhang 1 *, Shu-Ping Xiong 2, Shan Lu 1, Yi-Ye Wan 1, Rong-Feng Song 1. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.8.3111 Changes of CEA and CA199 Levels in Advanced Gastric Adenocarcinoma RESEARCH ARTICLE Changing patterns of Serum CEA and CA199 for Evaluating the Response
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationGallbladder Cancer. GI Practice Guideline. Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist)
Gallbladder Cancer GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist) Approval Date: September 2006 This guideline is a statement of
More informationEvaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: diagnosis and management of colorectal cancer 1.1 Short title Colorectal cancer 2 The remit The Department
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationAssociation of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients
Colorectal Cancer Association of Canada Learning about Colorectal Cancer A Personalized Treatment Guide for Patients Avastin is a trademark of Genentech, Inc., Used under licence. Camptosar is a registered
More informationIntegrating Oxaliplatin into the Management of Colorectal Cancer
Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationOriginal article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P.
Original article Annals of Oncology 15: 1013 1017, 2004 DOI: 10.1093/annonc/mdh267 Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationBy: Tania Cortas, MD Arizona Oncology 03/10/2015
By: Tania Cortas, MD Arizona Oncology 03/10/2015 Epidemiology In the United States, CRC incidence rates have declined about 2 to 3 percent per year over the last 15 years Death rates from CRC have declined
More information3 Summary of clinical applications and limitations of measurements
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin-16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018 DISCLAIMER Not a Substitute for Professional Advice This
More informationCase Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases
Case Reports in Oncological Medicine, Article ID 790192, 4 pages http://dx.doi.org/10.1155/2014/790192 Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Muhammad
More informationANTICANCER RESEARCH 35: (2015)
Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals IB JARLE CHRISTENSEN 1,2,5, NILS BRÜNNER
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationEfficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma
1931 Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma A 10-Year Experience of the Geisinger Medical Center Farid Fata, M.D. 1 Ayoub Mirza, M.D. 2 G. Craig Wood, M.S.
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationCLINICAL INVESTIGATION
Research Article CLINICAL INVESTIGATION Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationHorizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationCurrent standard in treatment of peritoneal carcinomotisis. Data behind the HIPEC trials
Current standard in treatment of peritoneal carcinomotisis Data behind the HIPEC trials Overview Peritoneal carcinomatosis STANDARD treatment HIPEC Results of treatment Counter side of treatment Peritoneal
More informationA clinical study of adjuvant chemotherapy in younger and elder rectal cancer patientsa
A clinical study of adjuvant chemotherapy in younger and elder rectal cancer patientsa The role of postoperative chemotherapy (CT) is still unclear and the evidence for recommendations of adjuvant therapy
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationPresent Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference
Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference Jpn J Clin Oncol 2010;40(Supplement 1)i38 i43 doi:10.1093/jjco/hyq125
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationA clinical study of metastasized rectal cancer treatment: assessing a multimodal approach
Med Oncol (2014) 31:839 DOI 10.1007/s12032-014-0839-1 ORIGINAL PAPER A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach Michaela Jung Annica Holmqvist Xiao-Feng Sun
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationRESEARCH ARTICLE. Joanne Chiu 1, Vikki Tang 1, Roland Leung 1, Hilda Wong 1, Kin Wah Chu 2, Jensen Poon 3, Richard J Epstein 4, Thomas Yau 1,3,5 *
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.11.6585 Adjuvant XELOX in Asian Patients with Colorectal Cancer RESEARCH ARTICLE Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationDisclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationSerum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer
Original Article DOI: 10.21276/awch.1782 Serum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer Mohd Rafey 1, Kafil Akhtar 1 *, Atia Z Rab 2 and Shahid A Siddiqui
More informationBevacizumab 10mg/kg 14 days
INDICATIONS FOR USE: Bevacizumab 10mg/kg 14 days Regimen Code 00212a *Reimbursement status Hospital INDICATION ICD10 In combination with fluoropyrimidine-based chemotherapy C18 for treatment of adult patients
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationDifference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution
Surg Today (2014) 44:1685 1691 DOI 10.1007/s00595-013-0748-5 ORIGINAL ARTICLE Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationThe diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer
European Review for Medical and Pharmacological Sciences 2017; 21: 4039-4044 The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer H.-Y. FAN
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More information